Few completed trials have directly tested the benefit of anti-inflammatory agents for vascular risk reduction. Convince aims to investigate the efficacy of low dose colchicine (0.5mg/day) plus usual care compared with usual care alone to prevent non-fatal recurrent ischaemic stroke, myocardial infarction, cardiac arrest, hospitalization for unstable angina and vascular death after ischaemic stroke or transient ischaemic attack (TIA) not caused by cardiac embolism or other defined causes unrelated to atherosclerosis.